Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;178(6):1316-1335.
doi: 10.1111/bph.15221. Epub 2020 Aug 31.

Protein kinase inhibitors for amyotrophic lateral sclerosis therapy

Valle Palomo  1   2 , Vanesa Nozal  1 , Elisa Rojas-Prats  1 , Carmen Gil  1   2 , Ana Martinez  1   2
Affiliations
Free article
Review

Protein kinase inhibitors for amyotrophic lateral sclerosis therapy

Valle Palomo et al. Br J Pharmacol. 2021 Mar.
Free article

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that causes the progressive loss of motoneurons and, unfortunately, there is no effective treatment for this disease. Interconnecting multiple pathological mechanisms are involved in the neuropathology of this disease, including abnormal aggregation of proteins, neuroinflammation and dysregulation of the ubiquitin proteasome system. Such complex mechanisms, together with the lack of reliable animal models of the disease have hampered the development of drugs for this disease. Protein kinases, a key pharmacological target in several diseases, have been linked to ALS as they play a central role in the pathology of many diseases. Therefore several inhibitors are being currently trailed for clinical proof of concept in ALS patients. In this review, we examine the recent literature on protein kinase inhibitors currently in pharmaceutical development for this diseaseas future therapy for AS together with their involvement in the pathobiology of ALS. LINKED ARTICLES: This article is part of a themed issue on Neurochemistry in Japan. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.6/issuetoc.

Keywords: ALS; CK-1d; Masitinib; Protein kinase inhibitors; Rapamycin; TDP-43.

PubMed Disclaimer

References

REFERENCES

    1. Ackerley, S., Grierson, A. J., Banner, S., Perkinton, M. S., Brownlees, J., Byers, H. L., … Miller, C. C. (2004). p38α stress-activated protein kinase phosphorylates neurofilaments and is associated with neurofilament pathology in amyotrophic lateral sclerosis. Molecular and Cellular Neurosciences, 26, 354-364. https://doi.org/10.1016/j.mcn.2004.02.009
    1. Aggarwal, S. P., Zinman, L., Simpson, E., McKinley, J., Jackson, K. E., Pinto, H., … Canadian Amyotrophic Lateral Sclerosis c. (2010). Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 9, 481-488. https://doi.org/10.1016/S1474-4422(10)70068-5
    1. Ahn, S. W., Kim, J. E., Park, K. S., Choi, W. J., Hong, Y. H., Kim, S. M., … Sung, J. J. (2012). The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice. Journal of the Neurological Sciences, 320, 1-5. https://doi.org/10.1016/j.jns.2012.05.038
    1. Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., … GTP collaborators. (2019). The concise guide to pharmacology 2019/2020: Nuclear hormones receptors. British Journal of Pharmacology, 176, S229-S246. https://doi.org/10.1111/bph.14748
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., … GTP collaborators. (2019). The Concise Guide to PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752

Publication types